Methods and materials for treating cancer

Abstract

This document provides methods and materials involved in treating cancer. For example, methods and materials for using a BiPE that can include (a) one or more molecules having the ability to bind to a cancer cell (e.g., a human breast cancer cell), (b) an optional linker component, and (c) one or more molecules having the ability to bind to an antigen presenting cell (e.g., a human macrophage) to treat cancer are provided.

1 - 14 . (canceled) 
     
     
         15 . A fusion polypeptide comprising a first amino acid segment having said ability to bind to cancer cells and a second amino acid segment having said ability to bind to antigen presenting cells, wherein incubation of said cancer cells and said antigen presenting cells in said presence of said fusion polypeptide results in increased phagocytosis of said cancer cells by said antigen presenting cells as compared to said level of phagocytosis of comparable cancer cells by comparable antigen presenting cells in said absence of said fusion polypeptide. 
     
     
         16 . The fusion polypeptide of  claim 15 , wherein said first amino acid segment is linked to said second amino acid segment via a linker amino acid sequence. 
     
     
         17 . The fusion polypeptide of  claim 15 , wherein said first amino acid segment having said ability to bind to cancer cells is an anti-cancer antigen antibody. 
     
     
         18 . The fusion polypeptide of  claim 17 , wherein said anti-cancer antigen antibody is an anti-CD340 antibody, an anti-EGFR antibody, or an anti-PSMA antibody. 
     
     
         19 . The fusion polypeptide of  claim 15 , wherein said second amino acid segment having said ability to bind to antigen presenting cells is a CRT polypeptide. 
     
     
         20 . The fusion polypeptide of  claim 19 , wherein said CRT polypeptide is a human CRT polypeptide. 
     
     
         21 . The fusion polypeptide of  claim 15 , wherein said cancer cells are breast cancer cells, brain cancer cells, prostate cancer cells, lung cancer cells, or colorectal cancer cells. 
     
     
         22 . The fusion polypeptide of  claim 15 , wherein said cancer cells are human breast cancer cells, human brain cancer cells, human prostate cancer cells, human lung cancer cells, or human colorectal cancer cells. 
     
     
         23 . The fusion polypeptide of  claim 15 , wherein said antigen presenting cells are macrophages. 
     
     
         24 . The fusion polypeptide of  claim 15 , wherein said antigen presenting cells are human macrophages. 
     
     
         25 . The fusion polypeptide of  claim 15 , wherein said increased phagocytosis is at least a two-fold increase. 
     
     
         26 . The fusion polypeptide of  claim 15 , wherein said increased phagocytosis is at least a four-fold increase. 
     
     
         27 . A method for treating a mammal having cancer, said method comprising administering to said mammal a fusion polypeptide of  claim 15 . 
     
     
         28 . The method of  claim 27 , wherein said mammal is a human. 
     
     
         29 . The method of  claim 27 , wherein said cancer is breast cancer, brain cancer, prostate cancer, lung cancer, or colorectal cancer. 
     
     
         30 . The method of  claim 27 , wherein said composition is administered by injection, ingestion, or inhalation.